S&P 500
(0.08%) 5 252.77 points
Dow J
(-0.07%) 39 733 points
Nasdaq
(0.04%) 16 405 points
Oil
(1.22%) $82.34
Gas
(1.46%) $1.743
Gold
(1.65%) $2 226.70
Silver
(0.12%) $24.78
Platinum
(1.21%) $920.70
USD/EUR
(0.23%) $0.925
USD/NOK
(0.57%) $10.83
USD/GBP
(0.00%) $0.791
USD/RUB
(0.08%) $92.52

Realtime updates for Bristol-Myers Squibb Co [BRM.DE]

Exchange: XETRA Sector: Pharmaceuticals Industry: Drug Manufacturers—General
Last Updated28 Mar 2024 @ 09:20

0.92% 49.45

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 09:20):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases...

Stats
Today's Volume 1 859.00
Average Volume 2 230.00
Market Cap 103.31B
EPS €0 ( 2024-02-02 )
Next earnings date ( €0 ) 2024-04-25
Last Dividend €0.570 ( 2023-07-06 )
Next Dividend €0 ( N/A )
P/E 14.13
ATR14 €0.153 (0.31%)

Bristol-Myers Squibb Co Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bristol-Myers Squibb Co Financials

Annual 2023
Revenue: €45.01B
Gross Profit: €34.31B (76.24 %)
EPS: €0
Q4 2023
Revenue: €11.48B
Gross Profit: €8.73B (76.08 %)
EPS: €0
Q3 2023
Revenue: €10.97B
Gross Profit: €8.46B (77.15 %)
EPS: €0.940
Q2 2023
Revenue: €11.23B
Gross Profit: €8.35B (74.38 %)
EPS: €0.990

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0
(N/A)
€0.540
(N/A)
€0.570
(N/A)
€0.570
(N/A)
€0.570
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Bristol-Myers Squibb Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.69 - Stable (13.89%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.215 1999-06-30
Last Dividend €0.570 2023-07-06
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 97 --
Total Paid Out €33.94 --
Avg. Dividend % Per Year 0.00% --
Score 4.93 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 5.69
Div. Directional Score 8.19 --
Next Divdend (Est)
(2024-05-08)
€0.580 Estimate 28.98 %
Dividend Stability
0.77 Good
Dividend Score
4.93
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
TNE5.DE Ex Dividend Junior 2023-12-12 Semi-Annually 0 0.00%
ETG.DE Ex Dividend Knight 2023-07-04 Annually 0 0.00%
NGLB.DE Ex Dividend Knight 2023-08-17 Semi-Annually 0 0.00%
AXA.DE Ex Dividend Junior 2023-05-08 Sporadic 0 0.00%
WAF.DE Ex Dividend Junior 2023-05-08 Annually 0 0.00%
GZF.DE Ex Dividend Junior 2023-04-28 Annually 0 0.00%
PND.F Ex Dividend Knight 2023-09-01 Quarterly 0 0.00%
CBHD.DE Ex Dividend Knight 2023-05-15 Semi-Annually 0 0.00%
IE2A.F Ex Dividend Junior 2023-05-02 Sporadic 0 0.00%
02M.DE Ex Dividend Knight 2023-09-06 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1781.5006.439.65[0 - 0.5]
returnOnAssetsTTM0.08431.2007.198.63[0 - 0.3]
returnOnEquityTTM0.2631.5008.1910.00[0.1 - 1]
payoutRatioTTM0.591-1.0004.09-4.09[0 - 1]
currentRatioTTM1.4270.8007.866.29[1 - 3]
quickRatioTTM1.2370.8007.435.94[0.8 - 2.5]
cashRatioTTM0.5151.5008.2510.00[0.2 - 2]
debtRatioTTM0.436-1.5002.74-4.11[0 - 0.6]
interestCoverageTTM8.081.0008.128.12[3 - 30]
operatingCashFlowPerShareTTM6.622.007.7910.00[0 - 30]
freeCashFlowPerShareTTM6.042.006.9810.00[0 - 20]
debtEquityRatioTTM1.409-1.5004.36-6.55[0 - 2.5]
grossProfitMarginTTM0.7621.0000.6270.627[0.2 - 0.8]
operatingProfitMarginTTM0.2091.0007.827.82[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3341.0009.259.25[0.2 - 2]
assetTurnoverTTM0.4730.800-0.180-0.144[0.5 - 2]
Total Score10.69

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM13.831.0008.700[1 - 100]
returnOnEquityTTM0.2632.508.8410.00[0.1 - 1.5]
freeCashFlowPerShareTTM6.042.007.9910.00[0 - 30]
dividendYielPercentageTTM2.151.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM6.622.007.7910.00[0 - 30]
payoutRatioTTM0.5911.5004.09-4.09[0 - 1]
pegRatioTTM0.2311.500-1.7940[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3081.0004.800[0.1 - 0.5]
Total Score5.69

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators